Please take a moment to review a new funding announcement from the MOHLTC.

We will be revising the EAP forms for Psoriatic Arthritis, Ankylosing Spondylitis and Rheumatoid Arthritis and will upload them onto the ontariorheum.ca website over the coming weeks.

Existing Exceptional Access Program Product with a New Indication
Cimzia (certolizumab pegol) 200mg/mL Pre-Filled Syringe (UCB) – Effective Date: April 14, 2016
For the treatment of Psoriatic Arthritis and Ankylosing Spondylitis, according to specific, current criteria.

Existing Exceptional Access Program Product with a New Dosage Form
Actemra (tocilizumab) 162mg/0.9mL Inj Sol Pre-Filled Syringed (HLR) – Effective Date: April 29, 2016
For the treatment of Rheumatoid Arthritis, according to specific criteria.